Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease Journal Article


Authors: Dhodapkar, M. V.; Osman, K.; Teruya-Feldstein, J.; Filippa, D.; Hedvat, C. V.; Iversen, K.; Kolb, D.; Geller, M. D.; Hassoun, H.; Kewalramani, T.; Comenzo, R. L.; Coplan, K.; Chen, Y. T.; Jungbluth, A. A.
Article Title: Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease
Abstract: Cancer/testis (CT) antigens are expressed in several malignant tumors, but not in normal tissues except for testicular germ cells. The expression of CT antigenic proteins in malignant gammopathies has not been characterized. We examined the expression of a panel of CT antigenic proteins in 29 patients with malignant gammopathies by immunohistochemistry using the following monoclonal antibodies (mAbs): mAb MA454 to MAGE-A1, mAb M3H67 to MAGE-A3, mAb 57B to MAGE-A4, mAb CT7-33 to CT7/MAGE-C1 and mAb ES121 to NY-ESO-1. We could detect at least one CT antigen in tumors from 27 of 29 patients. The expression pattern of MAGE-A1, -A3, -A4 and NY-ESO-1 is heterogeneous in most cases, revealing staining in <25% of the tumor cells. Monoclonal antibodies CT7-33 and M3H67 show the highest incidence of immunoreactivity. Importantly, CT-7 can also be detected on the surface of some myeloma cells by flow cytometry, and in one plasmacytoma case by immunohistochemistry. Expression of CT antigens is greater in patients with stage III extramedullary plasmacytoma or high-risk myeloma relative to other cohorts. These data suggest that CT antigens may have important biological implications in malignant gammopathies and that CT-7 may be a suitable target for T cell-based and possibly antibody-mediated immunotherapy of myeloma.
Keywords: immunohistochemistry; adult; clinical article; controlled study; human tissue; aged; unclassified drug; human cell; cancer localization; cancer risk; cancer staging; flow cytometry; antigen expression; multiple myeloma; plasmacytoma; immunoreactivity; monoclonal antibody; tumor antigens; cancer testis antigen; melanoma antigen 1; melanoma antigen 3; ny eso 1 antigen; antigen detection; immunophenotyping; genetic heterogeneity; melanoma antigen 4; genetic correlation; cell surface; cancer testis antigen 7; myeloma cell; monoclonal antibody 57b; monoclonal antibody m3h67; monoclonal antibody ma454; antigenicity; monoclonal antibody ct7 33; monoclonal antibody es121; gammopathy; prognosis; human; article; malignant plasmacytoma
Journal Title: Cancer Immunity
Volume: 3
ISSN: 1424-9634
Publisher: Academy of Cancer Immunology  
Date Published: 2003-07-23
Start Page: 1
End Page: 8
Language: English
PROVIDER: scopus
PUBMED: 12875607
DOI/URL:
Notes: Export Date: 12 September 2014 -- Source: Scopus